Adjuvant treatment of postmenopausal women w/ hormone receptor +ve invasive early breast cancer. Extended adjuvant treatment of invasive early breast cancer in postmenopausal women who have received prior standard adjuvant tamoxifen therapy for 5 yr. 1st-line treatment in postmenopausal women w/ hormone-dependent advanced breast cancer. Advanced breast cancer after relapse or disease progression in women w/ natural or artificially induced postmenopausal endocrine status who have previously been treated w/ anti-estrogens. Neo-adjuvant treatment of postmenopausal women w/ hormone receptor +ve, HER-2 -ve breast cancer where chemotherapy is not suitable & immediate surgery not indicated.
Not indicated in hormone receptor -ve disease. Monitor overall bone health during treatment. Measure LH, FSH &/or estradiol levels prior to treatment in patients whose postmenopausal status is unclear. Avoid co-administration w/ tamoxifen, other anti-estrogens or estrogen-containing therapies. Renal impairment (CrCl <10 mL/min). Severe hepatic impairment (Child-Pugh score C). Caution when driving or using machines. Sexually-active females of reproductive potential should use effective contraception during & for 20 days after treatment. May impair fertility in males of reproductive potential. Not recommended in childn & adolescents up to 17 yr.
Sign Out
